Design, synthesis and biological evaluation of bivalent ligands against A 1-D 1 receptor heteromers

Acta Pharmacologica Sinica

Volumn 34, Issue 3, 2013, Pages 441-452

  Shen, Jian ^a   Zhang, Lei ^a   Song, Wan Ling ^a   Meng, Tao ^a   Wang, Xin ^a   Chen, Lin ^a   Feng, Lin Yin ^a   Xu, Ye Chun ^a   Shen, Jing Kang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

A1 receptor; adenosine; bivalent ligands; D1 receptor; dopamine; FRET; G protein coupled receptors; heterodimers; molecular modeling; radiolabeled binding assay

Indexed keywords

2 (3,4 DIMETHOXYPHENETHYLAMINO) 1 (4 NITROPHENYL)ETHANOL; 2 (4 NITROPHENYL)OXIRANE; 2 BROMO 1 (4 NITROPHENYL)ETHANONE; 26 AZATRIACONTYL)HEXANAMIDE; 3 (3 HYDROXYPROPYL) 8 (NAPHTHALEN 2 YL) 1 PROPYL 1H PURINE 2,6(3H,7H) DIONE; 4 (7,8 DIMETHOXY 2,3,4,5 TETRAHYDRO 1H BENZO[D]AZEPIN 1 YL)ANILINE; 4,7,10,13,16 PENTAOXANONADECANE 1,19 DIAMINE; 4,7,10,13,16 PENTAOXANONADECANE 1,19 DIAMINE TETRAHYDROPYRIMIDIN 5 YL) 2 NAPHTHAMIDE; 4,7,10,13,16 PENTAOXANONADECANE 1,19 DINITRILE; 4,7,10,13,16,19,22 HEPTAOXAPENTACOSANE DINITRILE; 6 (4 (7,8 BIS(METHOXYMETHOXY) 2,3,4,5 TETRAHYDRO 1H BENZO[D]AZEPIN 1 YL)PHENYLAMINO) N (24 (8 (NAPHTHALEN 2 YL) 2,6 DIOXO 1 PROPYL 1H PURIN 3(2H,6H,7H) YL) 21 OXO 4,7,10,13,16 PENTAOXA 20 AZATETRACOSYL)HEXANAMIDE; 6 (4 (7,8 DIHYDROXY 2,3,4,5 TETRAHYDRO 1H BENZO[D]AZEPIN 1 YL)PHENYLAMINO) N (24 (8 (NAPHTHALEN 2 YL) 2,6 DIOXO 1 PROPYL 1H PURIN 3(2H,6H,7H) YL) 21 OXO 4,7,10,13,16 PENTAOXA 20 AZATETRACOSYL)HEXANAMIDE; 6 (4 (7,8 DIHYDROXY 2,3,4,5 TETRAHYDRO 1H BENZO[D]AZEPIN 1 YL)PHENYLAMINO) N (30 (8 (NAPHTHALEN 2 YL) 2,6 DIOXO 1 PROPYL 1H PURIN 3(2H,6H,7H) YL) 27 OXO 4,7,10,13,16,19,22 HEPTAOXA 26 AZATRIACONTYL)HEXANAMIDE; 7,8 DIMETHOXY 1 (4 NITROPHENYL) 2,3,4,5 TETRAHYDRO 1H BENZO[D]AZEPINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; ETHYL6 (N (4 (7,8 DIHYDROXY 3 (2 NITROPHENYLSULFONYL) 2,3,4,5 TETRAHYDRO 1H BENZO[D]AZEPIN 1 YL)PHENYL) 2 NITROPHENYLSULFONAMIDO)HEXANOATE; N (19 AMINO 4,7,10,13,16 PENTAOXANONADECYL) 4 (8 (NAPHTHALEN 2 YL) 2,6 DIOXO 1 PROPYL 1H PURIN 3(2H,6H,7H) YL)BUTANAMIDE; N (24 (8 (NAPHTHALEN 2 YL) 2,6 DIOXO 1 PROPYL 1H PURIN 3(2H,6H,7H) YL) 21 OXO 4,7,10,13,16 PENTAOXA 20 AZATETRACOSYL)HEXANAMIDE; N (25 AMINO 4,7,10,13,16,19,22 HEPTAOXAPENTACOSYL) 4 (8 (NAPHTHALEN 2 YL) 2,6 DIOXO 1 PROPYL 1H PURIN 3(2H,6H,7H) YL)BUTANAMIDE; N (30 (8 (NAPHTHALEN 2 YL) 2,6 DIOXO 1 PROPYL 1H PURIN 3(2H,6H,7H) YL) 27 OXO 4,7,10,13,16,19,22 HEPTAOXA 26 AZATRIACONTYL)HEXANAMIDE; N (4 (7,8 DIMETHOXY 3 (2 NITROPHENYLSULFONYL) 2,3,4,5 TETRAHYDRO 1H BENZO[D]AZEPIN 1 YL)PHENYL) 2 NITRO N (PENT 4 YNYL)BENZENE SULFONAMIDE; N (4 (7,8 DIMETHOXY 3 (2 NITROPHENYLSULFONYL) 2,3,4,5 TETRAHYDRO 1H BENZO[D]AZEPIN 1 YL)PHENYL) 2 NITROBENZENESULFONAMIDE; SKF38393; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN MEMBRANE; CONTROLLED STUDY; DIMERIZATION; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR DOCKING; MOLECULAR MODEL; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; BINDING, COMPETITIVE; BRAIN; DOPAMINE AGONISTS; DRUG DESIGN; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEK293 CELLS; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A1; RECEPTORS, DOPAMINE D1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84874601534     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.151     Document Type: Article

References (30)

1. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 2004; 66: 1-7.
2. Carriba P, Navarro G, Ciruela F, Ferre S, Casado V, Agnati L, et al. Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat Methods 2008; 5: 727-33.
3. George SR, O'Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 2002; 1: 808-20.
4. Milligan G. G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. Drug Discov Today 2006; 11: 541-9.
5. Franco R. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. PNAS 2000; 97: 8606-11.
6. Franco R, Lluis C, Canela EI, Mallol J, Agnati L, Casadó V, et al. Receptor-receptor interactions involving adenosine A1 or dopamine D1 receptors and accessory proteins. J Neural Transm 2007; 114: 93-104.
7. Popoli P, Gimenez-Llort L, Pezzola A, Reggio R, Martinez E, Fuxe K. Adenosine A1 receptor blockade selectively potentiates the motor effects induced by dopamine D1 receptor stimulation in rodents. Neurosci Lett 1996; 218: 209-13.
8. Liu Z, Zhang J, Zhang A. Design of multivalent ligand targeting G-protein-coupled receptors. Curr Pharm Des 2009; 15: 682-718.
9. Russo O, Berthouze M, Giner M, Soulier JL, Rivail L, Sicsic S, et al. Synthesis of specific bivalent probes that functionally interact with 5-HT(4) receptor dimers. J Med Chem 2007; 50: 4482-92.
10. Christopoulos A, Grant MK, Ayoubzadeh N, Kim ON, Sauerberg P, Jeppesen L, et al. Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther 2001; 298: 1260-8.
11. Peng X, Neumeyer JL. Kappa receptor bivalent ligands. Curr Top Med Chem 2007; 7: 363-73.
12. Soriano A, Ventura R, Molero A, Hoen A, Casado V, Cortes A, et al. Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers. J Med Chem 2009; 52: 5590-602.
13. Miiller C, Schobert U, Hipp J, Geis U, Frobenius W, Pawlowski M. Configurationally stable analogs of styrylxanthines as A2A adenosine receptor antagonists. Eur J Med Chem 1997; 32: 709-19.
14. González MP, Terán C, Teijeira M. Search for new antagonist ligands for adenosine receptors from QSAR point of view. How close are we? Med Res Rev 2008; 28: 329-71.
15. Neumeyerc JL, Kula NS, Bergman J, Baldessarini RJ. Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines. Eur J Pharmacol 2003; 474: 137-40
16. Zhang J, Xiong B, Zhen XC, Zhang A. Dopamine D1 receptor ligands: Where are we now and where are we going? Med Res Rev 2009; 29: 272-94.
17. Jiarpinitnun C, Kiessling L. Unexpected enhancement in biological activity of a GPCR ligand induced by an oligoethylene glycol substituent. J Am Chem Soc 2010; 132: 8844-5.
18. Mammen M, Shakhnovich E, Whitesides G. Using a convenient, quantitative model for torsional entropy to establish qualitative trends for molecular processes that restrict conformational freedom. J Org Chem 1998; 63: 3168-75.
19. Huber D, Lober S, Hubner H, Gmeiner P. Bivalent molecular probes for dopamine D2-like receptors. Bioorg Med Chem 2012; 20: 455-66.
20. Bakthavachalam V, Baindur N, Madras BK, Neumeyer JL. Fluorescent probes for dopamine receptors: synthesis and characterization of fluorescein and 7-nitrobenz-2-oxa-l,3-diazol-4-y conjugates of D-1 and D-2 receptor ligands. J Med Chem 1991; 34: 3235-41.
21. Wu P, Brand L. Resonance energy transfer: methods and applications. Anal Biochem 1994; 218: 1-13.
22. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008; 322: 1211-7.
23. Okada T, Sugihara M, Bondar AN, Elstner M, Entel P, Buss V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J Mol Biol 2004; 342: 571-83.
24. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al. High-resolution crystal structure of an engineered human beta(2)-adrenergic G protein-coupled receptor. Science 2007; 318: 1258-65.
25. Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V, et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 2011; 475: 65-70.
26. Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, Reinhart G, et al. Crystal structure of a lipid G protein-coupled receptor. Science 2012; 335: 851-5.
27. Chien EY, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010; 330: 1091-5.
28. Tarakanov AO, Fuxe KG. Triplet puzzle: homologies of receptor heteromers. J Mol Neurosci 2010; 41: 294-303.
29. Tarakanov AO, Fuxe KG. The triplet puzzle of homologies in receptor heteromers exists also in other types of protein-protein interactions. J Mol Neurosci 2011; 44: 173-7.
30. Kuhhorn J, Hubner H, Gmeiner P. Bivalent dopamine D2 receptor ligands: synthesis and binding properties. J Med Chem 2011; 54: 4896-903.